Compare CDW Corp. (CDW) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Citius Pharmaceuticals Inc — how do they compare? CDW Corp. trades at $135.37 (market cap $16.92B), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: CDW Corp. is far larger — about 845.6× Citius Pharmaceuticals Inc's market cap, and CDW Corp. pays a 1.86% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CDW | CTXR | |
|---|---|---|
Market Cap | $16.92B | $20.01M |
Sector | Technology | Health |
52-Week High | $170.77 | $1.82 |
52-Week Low | $99.30 | $0.48 |
Enterprise Value | $22.52B | $16.23M |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $136.83, up 0.29% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.91, beating estimates, driven by 10% revenue growth from AI and infrastructure demand. However, margin compression and a CFO transition plan for 2027 present headwinds. The stock shows strong analyst support with a 70.59% buy rating and a $148.67 consensus price target.
Outlook remains positive due to solid fundamentals and AI-driven growth, but risks include margin pressure and leadership changes. The stock offers potential upside to the price target, though investors should monitor execution on profitability amid competitive and macroeconomic challenges.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
